DAC 0060

Drug Profile

DAC 0060

Alternative Names: DAC-0060; DAC-060; DAC60

Latest Information Update: 12 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DAC Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer

Most Recent Events

  • 12 Feb 2016 Phase-II development for Basal cell cancer is ongoing in Italy
  • 30 Oct 2013 Phase-II clinical trials in Basal cell cancer (Combination therapy) in Italy (Topical)
  • 14 Oct 2010 DAC 0060 is available for out-licensing (http://www.genextra.it/partnering.html)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top